These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 20524302

  • 1. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Al Meshari K.
    Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
    [No Abstract] [Full Text] [Related]

  • 2. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
    Pavlakis M.
    Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
    Mai HL, Cesbron A, Brouard S, Blanchol G, Cantarovich D, Dantal J, Hourmant M, Lino M, Meurette A, Gosselin M, Abbadie O, Soulillou JP, Giral M.
    Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
    [No Abstract] [Full Text] [Related]

  • 4. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
    Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS.
    Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
    [No Abstract] [Full Text] [Related]

  • 5. Bortezomib rescue in refractory acute humoral rejection--report of a case.
    Shapiro R, Basu A, Zeevi A, Lunz J, Mapara M, Randhawa P, Morgan C, Tan HP, Sharma V.
    Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
    [No Abstract] [Full Text] [Related]

  • 6. Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report.
    Manitpisitkul W, Wilson N, Cooper M, Gurk-Turner C, Hurley H, Rasetto F, KuKuruga D, Barth RN, Philosophe B.
    Clin Transpl; 2009; ():461-3. PubMed ID: 20524315
    [No Abstract] [Full Text] [Related]

  • 7. Use of bortezomib for prevention and treatment of rejection in sensitized patients.
    Hartono C, Lubetzky M, Aull MJ, Saal S, Figueiro J, Kapur S, Dadhania D.
    Clin Transpl; 2009; ():499-503. PubMed ID: 20524323
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
    Lee I, Constantinescu S, Gillespie A, Swami A, Birkenbach M, Leech S, Silva P, Karachristos A, Daller JA, Sifontis NM.
    Clin Transpl; 2009; ():425-9. PubMed ID: 20524309
    [No Abstract] [Full Text] [Related]

  • 9. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Terasaki PI.
    Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases.
    Cooper JE, Wiseman AC, Chan L.
    Clin Transpl; 2009; ():455-9. PubMed ID: 20524314
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL, Murillo D.
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [Abstract] [Full Text] [Related]

  • 13. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES.
    Transplantation; 2010 Feb 15; 89(3):277-84. PubMed ID: 20145517
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
    Leyva S, Marino-Vázquez LA, Reyes-Loaeza JA, Vega O, Uribe-Uribe N, Alberú J, Morales-Buenrostro LE.
    Clin Transpl; 2009 Feb 15; ():369-76. PubMed ID: 20524300
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M, Couvrat-Desvergnes G, Castagnet S, Cesbron A, Renaudin K, Cantarovich D, Giral M.
    Transplantation; 2015 Jan 15; 99(1):63-8. PubMed ID: 25029384
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K, Pall A, Elgamal H, Alzayer F, Altalhi M.
    Clin Transpl; 2010 Jan 15; ():383-90. PubMed ID: 21696055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.